Rivfloza (nedosiran) prior authorization
UnitedHealthcare prior authorization policy for Rivfloza (nedosiran) governing initial authorization and reauthorization criteria for medical-benefit use in primary hyperoxaluria type 1 (PH1), including age and kidney function requirements, prohibition of concomitant use with lumasiran (Oxlumo), and authorization duration.
Updated age limitation based on FDA-labeled indication.
Specified program as Prior Authorization/Notification and medical-benefit for prior UHC PA bypass.
Annual review in 5/2025 showed no changes to coverage criteria.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.